| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Schabel FM Jr | |
| F. M. Schabel | |||
| P2860 | cites work | Cancer Research | Q326097 |
| Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer | Q34162335 | ||
| Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer | Q36312088 | ||
| Concepts for treatment of micrometastases developed in murine systems | Q36932448 | ||
| Adjuvant therapy-theory, practice, and potential. The James Ewing lecture | Q39365896 | ||
| 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings | Q66903287 | ||
| Concepts for systemic treatment of micrometastases | Q66906594 | ||
| Amputation and Adriamycin in Primary Osteosarcoma | Q69055787 | ||
| Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma | Q69356736 | ||
| Kinetics of mammary tumor cell growth and implications for therapy | Q70622373 | ||
| Influence of the concentration of leukemic inoculum on the effectiveness of treatment | Q74050355 | ||
| P433 | issue | 6 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncology | Q162555 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 2875-2882 | |
| P577 | publication date | 1977-06-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Rationale for adjuvant chemotherapy | |
| P478 | volume | 39 |
| Q73488908 | Adjuvant chemotherapy for non-small cell lung cancer |
| Q69805368 | Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM |
| Q40376828 | Adjuvant chemotherapy for soft tissue sarcomas. |
| Q44255513 | Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year resu |
| Q67254601 | An analysis of the role of radiotherapy alone and in combination with chemotherapy and surgery in the management of advanced breast carcinoma |
| Q88230168 | Chemotherapy Programs of the National Prostatic Cancer Project (NPCP) |
| Q34307782 | Circulating tumor cells: from bench to bedside |
| Q33479138 | Cisplatin as adjunctive treatment for invasive bladder carcinoma: tolerance and toxicities. |
| Q41165817 | Combination Chemotherapy in Advanced Postmenopausal Mammary Carcinoma: A comparison between VAC and VACM therapy |
| Q39800715 | Combined Modality Management of Operable Breast Cancer |
| Q34289090 | Cytotoxic chemotherapy for common adult malignancies: "the emperor's new clothes" revisited? |
| Q33678970 | Detection and clinical importance of micrometastatic disease |
| Q46291183 | Detection of occult bone marrow micrometastases in patients with operable lung carcinoma |
| Q40829473 | Detection of occult metastases in lung carcinomas: progress and implications for lung cancer staging |
| Q34465205 | Detection of occult metastasis in patients with breast cancer |
| Q35601592 | Evaluation of bone marrow in breast cancer patients: prediction of clinical outcome and response to therapy |
| Q73739489 | Flynn et al.: does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? |
| Q38219831 | Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma |
| Q34465224 | Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer |
| Q34778895 | Multimodal treatment in operable breast cancer: five-year results of the CMF programme. |
| Q41460411 | New approaches to the integrated management of early lung cancer |
| Q43795666 | New strategies in cancer chemotherapy |
| Q34274524 | Occult metastasis |
| Q72604805 | Palliative therapy for metastatic breast cancer |
| Q39708318 | Phase I–II study of concurrent irradiation and multi-drug chemotherapy in advanced carcinoma of the breast: A pilot study by the Southeastern Cancer Study Group |
| Q34203829 | Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells |
| Q72528112 | Rapid growth rate in breast cancer: a confounding variable in adjuvant-chemotherapy trials |
| Q54688142 | Sequential assays of hormone receptors and the Tritiated Thymidine Labeling Index in 7,12-dimethylbenz(a)anthracene-induced rat mammary cancers. |
| Q41404291 | Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer |
| Q35949551 | The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform |
| Q30245342 | The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis |
| Q28477876 | Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy |
Search more.